Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


European Medicines Agency 

7 Westferry Circus
Canary Wharf
London    E14 4HB  United Kingdom
Phone: 44-0-20-7523-7600 Fax: n/a



 Company News
European Medicines Agency Accepts TiGenix Pediatric Investigation Plan For Cx601 9/8/2014 7:43:41 AM
Cerenis Therapeutics, Inc. Receives European Medicines Agency Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies 9/3/2014 12:44:17 PM
Nuvilex (NVLX) Submits Application For Orphan Drug Designation To The European Medicines Agency For Its Cell-In-A-Box® Treatment For Pancreatic Cancer 9/2/2014 10:41:03 AM
Takeda Pharmaceutical Co. Ltd. (TKPYY) Announces Completion Of The Post-Marketing Commitment To Submit Data To The FDA, The European Medicines Agency And The PMDA For Pioglitazone Containing Medicines Including ACTOS 8/28/2014 11:09:59 AM
Cubist Pharmaceuticals, Inc. (CBST) Announces European Medicines Agency Acceptance Of Ceftolozane/Tazobactam Marketing Authorization Application For Review 8/22/2014 10:49:38 AM
European Medicines Agency Accepts Application Seeking New Indication For Pfizer Inc. (PFE)'s Prevenar 13®1 For Prevention Of Pneumococcal Pneumonia In Adults 8/7/2014 11:07:00 AM
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval Of IMBRUVICA® (Ibrutinib) For Treatment Of Two Blood Cancers 7/25/2014 8:02:37 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: European Medicines Agency Accepts Marketing Authorization Application For Asfotase Alfa As A Treatment For Patients With Hypophosphatasia 7/24/2014 11:41:16 AM
Sigma-Tau Rare Disease Submits Application To The European Medicines Agency For Use Of PegylatedL-Asparaginase (Oncaspar®) In The Treatment Of Acute Lymphoblastic Leukaemia 7/10/2014 10:26:15 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Announces European Medicines Agency Acceptance Of Pediatric Investigation Plan For Qinprezo™ (Vosaroxin) For AML 7/9/2014 10:45:28 AM